Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...
Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback